Dr Arnaud Didierlaurent | Head Adjuvant Platform
GSK Vaccines

Dr Arnaud Didierlaurent, Head Adjuvant Platform, GSK Vaccines


DC Co-conference Day 2 April 4 @ 09:10

Novel adjuvants: What’s needed and how to get them approved?

  • Future of adjuvants – what is needed?
  • The need for a better strategy for a rational design
  • Developing adjuvants to improve existing vaccines & reduce the amount of vaccine antigen needed
  • New mechanism of adjuvant; Inducible adjuvant mediated by multiple, but specific pathways

back to speakers